AIBC is delighted to welcome our esteemed faculty.
- Robyn Box
Dr Robyn Box MPhty PhD
APA Cancer Care and Lymphoedema Physiotherapist
Robyn has worked in Cancer Care and Lymphoedema for over 35 years in public and private health care settings, completing her PhD in 2000 investigating the effects of Physiotherapy for Breast Cancer Rehabilitation and Early Detection of Lymphoedema introduced initially in 1993. Robyn’s commitment to providing individualized evidence-based best practice culminated in opening a private clinic in 2005, translating her prospective surveillance model into clinical practice. Physiotherapy rehabilitation, exercise prescription, lymphoedema awareness and early detection and management is integral to optimizing health and well-being for patients diagnosed with cancer and/or lymphoedema as part of the “MOVES for Life” programme offered.
- Andrew Broadbent
Associate Prof Andrew Broadbent BMedSc, MBChB (Otago), MHM (UNSW) FRACP, FAChPM,
Andrew is the Medical Director of the Supportive and Specialist Palliative Services at Gold Coast Health He moved in 2016 from Royal North Shore Hospital and Hammondcare in Northern Sydney.
He has a long-term interest in developing best practice services through redesign and change He has a Master of Health Management at the University of New South Wales that helped give him the theoretical knowledge to do this best as possible along with the practical experience in hospital management at Prince of Wales Hospital in Sydney and that of a Director of Specialist Palliative services for nearly 20 years.
He is the acting chair of the Queensland Health Statewide Palliative Care Network, a member of the Statewide Directors group for Palliative Care in Queensland and a member of the Clinical Council at Gold Coast Health and is an Honorary Adjunct Associate Professor at Bond University
- Raymond Chan
Prof Ray Chan (RN, PhD, FACN) is Chair in Cancer Nursing, jointly appointed by Princess Alexandra Hospital, Metro South Health and Queensland University of Technology. Prof Chan’s research program focuses on optimising models of care and health services’ responses to address the needs of people affected by cancer in the survivorship phase. Prof Chan has published 140 peer-reviewed articles. In total, he has attracted >$21.5 million AUD of research funding as Chief Investigator. Prof Chan is an internationally recognised expert in cancer survivorship. He is the current Chair for the Multinational Association for Supportive Care in Cancer (MASCC) Survivorship Group.
- Boon H. Chua
Dr Boon H Chua is Professor of Medicine at UNSW Sydney; Consultant Radiation Oncologist, Director of Cancer and Haematology Services, and Medical Co-Director of the Program of Neurosciences, Cancer Services, Rehabilitation, Intensive Care, Radiology and Nuclear Medicine at the Prince of Wales Hospital in Sydney.With clinical and academic subspecialisation in breast cancer, Dr Chua leads a national and international program of competitive grant-funded oncology research in collaboration with cooperative clinical trials groups worldwide. She also holds leadership positions in a diverse range of national and international organisations including Executive Board member of Breast International Group, Education Faculty member of European Society of Medical Oncology, Scientific Advisory Committee Executive of Breast Cancer Trials-ANZ, and Breast Subspecialty Group Chair of Trans Tasman Radiation Oncology Group.Dr Chua was a senior clinical leader for redevelopment of Peter MacCallum Cancer Centre where she was Staff Specialist until November 2016. As Chair and Principal Council Representative of the RANZCR Post-Fellowship Education Committee, Dr Chua led development and implementation of the national program of continuing professional development in Radiation Oncology.
- Steven David
Steven David, Australia
- Sarah-Jane Dawson
Professor Sarah-Jane Dawson is a clinician-scientist. She obtained her medical degree from the University of Melbourne in 1998, and trained as a medical oncologist in Melbourne, Australia. She completed her PhD at the University of Cambridge, UK. Following postdoctoral studies at the Cancer Research UK Cambridge Institute, she returned to Melbourne in 2014 to head the Molecular Biomarkers and Translational Genomics Laboratory at the Peter MacCallum Cancer Centre. She also holds a joint appointment with the Centre of Cancer Research at The University of Melbourne (since 2016) and currently holds a CSL Centenary Fellowship (2018-2022). She is a fellow of the Australian Academy of Health and Medical Sciences and was recipient of the Jian Zhou Medal in recognition of translational medical science in 2020. Her current research interests are focused on the development of noninvasive blood-based biomarkers (‘liquid biopsies’) for clinical application, including early detection, risk stratification and disease monitoring in cancer management..
- Richard de Boer
Dr. Richard De Boer completed his basic medical and oncology training at the Royal Melbourne Hospital and then in 1997 undertook a 3-year breast and lung cancer clinical research fellowship at the Royal Marsden Hospital in London, working with Professor Ian Smith.
He returned to Melbourne in 2000 and since then has been a consultant medical oncologist working in both public and private practice. His primary areas of clinical interest are in breast and lung cancer, with breast cancer interests focusing on endocrine therapy and mechanisms of resistance, treatment-induced bone loss and bone metastases, and biological predictors of response/survival. He is actively involved in clinical research, and is a member of the Australian New Zealand Breast Cancer Trials Group, and head of the Breast Trials group of Cancer Trials Australia. He has authored or co-authored articles appearing in journals such as the Journal of Clinical Oncology, Annals of Oncology, The Breast and British Journal of Cancer.
- Rebecca Dent
Rebecca Dent is Senior Consultant in the Department of Medical Oncology, National Cancer Center Singapore and is Chief of the Breast Medical Oncology Service.
She is also an Associate Professor at Duke-National University Singapore Medical School. Dr Dent received her medical degree in 2000 from McMaster University in Hamilton, Canada, and obtained her Master of Science degree in clinical epidemiology and biostatistics from the University of Toronto, Canada. She obtained her internal medicine and medical oncology training at the University of Toronto, Canada.
Dr Dent’s primary research interest is in the field of breast cancer, focusing on locally advanced breast cancer and triple-negative breast cancers. She is principal investigator for several clinical trials for the treatment of preoperative and advanced breast cancer. She serves on a number of scientific committees at ASCO, ESMO and ESMO Asia.
- Elisabeth Elder
Elisabeth Elder is a specialist breast surgeon at the Westmead Breast Cancer Institute and Clinical Associate Professor at the University of Sydney, with a special interest in oncoplastic and reconstructive surgery. She is involved in numerous research projects and clinical trials within the Westmead Breast Cancer Research Collaborative. She graduated from the Karolinska Institute in Sweden in 1992, where she also completed her general surgery training and a PhD in tumour biology in 2002. She is the President of ASBD and previous chair of the oncoplastic committee of Breast Surgeon in Australia and New Zealand and council member of Breast Surgeons International. She regularly participates in breast cancer education for medical professionals, students as well as patient groups and the broader community.
- Jane Fox
Jane Fox, Australia
- Prudence Francis
Prudence Francis commenced Medical Oncology training in Australia and subsequently completed training in the USA. She spent 4 years at Memorial Sloan-Kettering Cancer Center in New York. In 1994 she was appointed as a Consultant Medical Oncologist at the Peter MacCallum Cancer Centre in Melbourne. Since 2003 she has been the Clinical Lead for Breast Medical Oncology at Peter MacCallum. She is Chair of the Scientific Advisory Committee of the Australia New Zealand Breast Cancer Trials Group (ANZ BCTG). She is a member of the Scientific Committee of the International Breast Cancer Study Group (IBCSG). She is a panel member on the Advanced Breast Cancer (ABC) International Consensus Panel and the St Gallen International Consensus Panel for Primary Therapy of Early Breast Cancer. As a clinician researcher she has focused much of her research on randomized breast cancer trials.
- Jemma Gilchrist
Dr. Jemma Gilchrist is a senior clinical psychologist who has a special interest in the emotional care of individuals with cancer and their families. Since 1999, Jemma has worked in cancer centres in the public and private sector. She is actively involved in research to develop new ways of treating common fears and concerns as well as optimising communication between patients and health care professionals. Jemma is currently working clinically at Crown Princess Mary Cancer Centre and her private practice, “Mind My Health”, in Sydney.
- Shom Goel
Dr. Shom Goel is a breast cancer physician-scientist at the Peter MacCallum Cancer Centre in Melbourne. He is known for his study of the cell cycle machinery and senescence in breast cancer, and in particular for elucidating key mechanisms by which CDK4/6 inhibitors exert their activity. His preclinical research has been published in journals such as Nature, Cancer Cell, and Nature Cancer, and has triggered the development of randomised controlled trials that are poised to change clinical practice.
- Phillip Good
Phillip Good, Australia
- Ben Green
Ben Green, Australia
- Paul James
Assoc Prof Paul A James is a Clinical Geneticist from Melbourne. He is the director of the Parkville Familial Cancer Centre (Royal Melbourne Hospital and Peter MacCallum Cancer Centre) and Head of Clinical Genetics in the Department of Genomic Medicine (RMH). He leads a program of clinical research including discovery and translational projects emphasising familial cancer and the genetics of inherited cardiac disorders, and is a group leader in Familial Cancer research at Peter MacCallum.
- Belinda Kiely
Belinda Kiely, Australia
- Louise Koelmeyer
Dr Louise Koelmeyer is the Director of the Australian Lymphoedema Education, Research and Treatment (ALERT) program at Macquarie University and is involved in strategically managing and developing the education, research and treatment arms of the innovative and internationally recognised “Centre of Excellence” multidisciplinary program. Louise is a lymphoedema therapist (Occupational therapist), educator and researcher with over 30 years of experience in both public and private settings specialising in breast cancer rehabilitation and lymphoedema management. Her area of interest is on the prospective surveillance and early intervention model of care for the early detection and management of lymphoedema as well as innovative advances in conservative and surgical management.
- Sunil R. Lakhani
Sunil Lakhani is a clinical diagnostic and molecular pathologist. He is the Executive Director of Research and Senior Staff Specialist at Pathology Queensland and Head of the Breast Group, University of Queensland Centre for Clinical Research (UQCCR), Brisbane, Australia. His current interests include lobular carcinoma and its variants, triple negative and metaplastic breast cancer and the mechanisms and therapeutic development of brain metastases.
He was Editor of the WHO 4th Ed Tumours of the Breast (2012) and is Editor and Standing member of Board of WHO 5th Ed Tumours of the Breast (2019). He is an elected Board member of Breast Cancer Trials.
He is the recipient of the Distinguished Pathologist Medal, Australasian Division of the International Academy of Pathology and The Distinguished Fellow Award, The Royal College of Pathologists of Australasia. In 2017, he was elected Fellow of the Australian Academy of Health and Medical Sciences.
- Brian Le
Brian Le is the Director of Palliative Care at the Victorian Comprehensive Cancer Centre, including the Peter MacCallum Cancer Centre and The Royal Melbourne Hospital.
He is a Palliative Medicine Physician and Medical Oncologist, and is an Associate Professor of the University of Melbourne.
Brian has published over 85 peer reviewed scientific papers and book chapters, is involved in palliative care research including clinical trials and health services research.
Brian is a past Chair of the Palliative Medicine Training Committee of the Royal Australasian College of Physicians, responsible for training of all palliative medicine specialists in Australia and New Zealand, and past Chair of Palliative Care Victoria.
- Rhea Liang
Rhea Liang, Australia
- Elgene Lim
Prof Elgene Lim is a medical oncologist at The Kinghorn Cancer Centre, St Vincent’s Hospital, and leads the Connie Johnson Breast Cancer Research Group at the Garvan Institute of Medical Research. He obtained his training at the University of Melbourne, Walter& Eliza Hall of Medical Research, and Dana-Farber Cancer Institute. He is the inaugural National Breast Cancer Foundation Endowed Chair and a clinical academic at the UNSW medical school. His research team performs clinically focused laboratory research, utilizing patient-derived breast tumour xenografts for the evaluation of novel therapies. A major focus of his group is on overcoming resistance to currently used endocrine therapies. His research is funded through the National Breast Cancer Foundation, Cancer Australia, Cancer Council of NSW, National Health and Medical Research Council, Love Your Sister, the Garvan, Balnaves, Curran and St Vincent’s Clinic Foundation.
- Jocelyn Lippey
Jocelyn Lippey is a breast surgeon from Melbourne, Victoria working at St. Vincent’s, The Northern hospital and BreastScreen as well as St. Vincent’s East Melbourne privately.She was a current recipient of an NBCF practitioners grant to develop a risk communication tool for risk-stratified Breast screening which is also her PhD thesis due to finish in late 2020. She also co-ordinates a unit of study for University of Sydney’s Masters of Breast Surgery.Her research interests include DCIS, risk communication and tailored breast screening.
- Sherene Loi
Sherene Loi MBBS (Hons), PhD, FRACP, FAHMS
I am a Medical Oncologist specialized in breast cancer treatment as well as a clinician scientist with expertise in genomics, immunology and drug development. I am recognised internationally as a leading clinician scientist whose work has led to new insights into the breast cancer immunology field.
After completing Medical Oncology specialist clinical training in Melbourne, I undertook a PhD and postdoctoral studies at the Institut Jules Bordet in Brussels, Belgium. In 2013, I returned to a Group Leader position at the Peter MacCallum Cancer Centre in Melbourne, as well as Consultant Medical Oncologist in the Breast Service and head of the Breast Cancer Clinical Trials Unit.
To date, I have published over 220 peer-reviewed research articles with a lifetime H index of 79. My recent work has been highly influential with 30,617 total citations and 23,711 (77%) within the past 5 years. I am ranked in the top 1% of highly cited researchers globally by the Web of Science. I am a Board Director as well as a member of the Scientific Advisory Committee of the Australia New Zealand Breast Cancer Trials Group (BCT Australia/NZ), which is the largest breast cancer clinical trials cooperative group in Australia. I Co-Chair the Scientific Executive Committee of the International Breast Cancer Study Group (IBCSG) based in Bern, Switzerland which conducts academic global breast cancer clinical trials in over 16 countries. I am the current holder of the Inaugural National Breast Cancer Foundation (NBCF) of Australia Endowed Chair and a research fellow of the Breast Cancer Research Foundation (BCRF), New York.
- Douglas MacMillan
Douglas MacMillan, UK
- Bruce Mann
Prof. Bruce Mann is Professor of Surgery at the University of Melbourne and Director of The Breast Service at the Royal Melbourne and Royal Women’s Hospital in Melbourne. He is on the council of Breast SurgANZ, the Scientific Advisory Committee of the ANZ Breast Cancer Trials Group and is past president of the Clinical Oncology Society of Australia. He has been involved in many clinical trials and much clinical and translational research regarding breast cancer, with his main research interest being tailoring treatment to the disease and the patient.
- Ritse Mann
Ritse Mann is a breast and interventional radiologist, working at the Radboud University Medical Centre in Nijmegen, as well as the Netherlands Cancer Institute in Amsterdam. He leads clinical radiological breast research at both hospitals. He is currently chair of the scientific committee of the European Society of breast imaging (EUSOBI), and section editor Women’s Imaging for the European Journal of Radiology. He is course director of the annual Nijmegen Advanced Breast Imaging Course, as well as the Cairo based course DETECT, has been member of the program planning committee for breast for ECR from 2012-2015 and is currently member of the scientific program planning committee for breast of the RSNA. He leads and participates in many clinical trials on the clinical value of new and existing imaging modalities for detection and classification of breast lesions, with a particular focus on breast MRI.
- Nicole McCarthy
Associate Professor Nicole McCarthy MBBS (Hons), MHSc, FRACP is a Consultant Medical Oncologist at Icon Cancer Care at the Wesley Medical Centre and Wesley Hospital in Brisbane and her academic appointment is with the School of Medicine, University of Queensland . She completed a 3 year Medical oncology fellowship at the National Cancer Institute, Bethesda MD and a Masters in Health Sciences in Clinical Trial Design through Duke University. She is an academic clinician and her clinical practice and translational research focuses on the multifaceted aspects of breast cancer care and management. She led the Breast Cancer Clinical trials unit at the Royal Brisbane and Women’s Hospital for over 10 years and now provides leadership for the breast cancer clinical trials component of ICON Research Foundation Clinical Trials Unit, the largest national private oncology provider. A/Prof McCarthy is considered an opinion leader in breast cancer management at a local and national level and her own investigator-initiated clinical trials have been incorporating new agents into neoadjuvant breast cancer treatment. A/Prof McCarthy has been the Chair of the Systemic Therapy Subcommittee of the ANZ Breast Cancer Trials Group Scientific Advisory Committee (SAC) since 2007 and a member of the SAC since 2004. She has been the Australian Principal Investigator on several international clinical trials. A/Prof McCarthy has been a member of a number of national breast cancer guideline panels and has played a close role with breast cancer consumer advocacy groups.
- Carolyn Nickson
Carolyn Nickson, Australia
- Kerry Patford
Kerry Patford brings more than 30 years’ of nursing experience to her role as the Chief Clinical Leader for the McGrath Foundation where she provides support and advice and assists in the professional development of McGrath Breast Care Nurses right across Australia.
Kerry leads a team of Clinical Leaders to deliver key projects around breast care nursing practice, professional development and support to over 160 McGrath Breast Care Nurses. She maintains her clinical currency practising as a McGrath Breast Care Nurse in regional Victoria and provides leadership and expertise to other cancer care organisations, universities and governments, consulting on a range of projects to improve care and treatment for patients and their families.
- Nirmala Pathmanathan
Associate Professor Nirmala Pathmanathan, BSc (Med), MB, BS, FRCPA, MIACAssociate Professor Nirmala Pathmanathan is an anatomical pathologist with expertise in breast diseases. She is the Director of the Westmead Breast Cancer Institute in Sydney, which is a comprehensive multidisciplinary breast cancer program covering Western Sydney. She is also the Director of the BreastScreen Program for Sydney West and the Designated/Lead Pathologist for this program. She is a Clinical Associate Professor with the University of Sydney and Conjoint Associate Professor with the University of Western Sydney. A/Prof Pathmanathan is currently a specialist breast pathologist at Douglass Hanly Moir Pathology (part time).
A/Professor Pathmanathan is the recipient and chief or principal investigator on a number of grant-funded projects and is a past executive committee member of the Australian Breast Cancer Tumour Bank. She is a Member of NBOCC Sentinel Node Biopsy Subgroup and was involved in the development of recommendations for use of Sentinel Node Biopsy in Breast Cancer. Recently, A/Professor Pathmanathan has been a steering committee member in the development and presentation of breast cancer workshops, aimed at improving the quality of breast cancer pathology and HER2 testing in several countries across the Asia Pacific Region. She sits on the Executive Committee for the Australasian Society for Breast Diseases and is a National Clinical Advisory Board Member for BreastScreen Australia. Her primary research interests are in HER2 testing, prognostic markers in ER positive breast cancer and borderline/atypical lesions of the breast.
- Kirsten Pilatti
Chief Executive Officer
Kirsten Pilatti was appointed CEO in March 2018.
She has an exceptional understanding of the cancer sector having spent over a decade at BCNA.
Highly regarded for her passion and focus on Australian women and men who have been affected by breast cancer, she is committed to giving everyone a voice and reducing the disparity of care across the country.
Her deep connection to our 150,000 members was cemented after spending 18 months travelling around Australia interviewing more than 3,500 women and men about their experience of breast cancer treatment and services to find out where the gaps in service delivery are occurring. The findings were outlined in the State of the Nation report, which was delivered to Federal Parliament in June 2018.
She is also proud of the work she has done to turn the spotlight on important issues such as access to breast reconstruction, the out of pocket costs experienced by breast cancer patients, driving changes to the Australian healthcare system including access to drugs through the PBS such as the CDK inhibitors for Australians with metastatic breast cancer.
Kirsten understands the power of sharing the experiences of those diagnosed and living with breast cancer. She will continue to be their advocate until all Australians receive the very best care, treatment, and support.
Born and raised in Western Australia, Kirsten lives in Melbourne with her partner and two sons.
- Philip Poortmans
Philip Poortmans MD PhD
In 1986 I completed my medical studies at the University of Antwerp, Belgium. I was trained as a radiation oncologist at the Middelheim and Vincentius Hospitals in Antwerp.
In 1991 I started as a radiation oncologist in Tilburg, The Netherlands. After chairing for 2.5 years the department of radiation oncology of the Radboud umc, Nijmegen, I took the same position at Institut Curie, Paris, France, in March 2017, which I left in November 2019. On the 150th birthdate of Marie Curie I was nominated Marie Curie Professor Paris Science & Lettres – Institut Curie. In April 2020 I started a part-time medical advisory function for Sordina IORT Technologies spa. In July 2020, I started as radiation oncologist at Iridium Netwerk. Since October 2020, I am associate professor at the University of Antwerp, Belgium.
Special interests: breast cancer, FLASH radiation therapy, IOeRT, malignant lymphoma and rare tumours.
In 2005: PhD thesis on quality assurance in clinical trials in breast cancer at the University of Maastricht.
Since 1992 active in the EORTC, currently member of the Lymphoma and Breast Groups; secretary Radiation Oncology Group (2006-2015); Quality Assurance Committee of the EORTC (2003-2015).
2005 – 2008: councillor of the board of ESTRO.
2007 – 2010: representative for radiation oncology in the Multidisciplinary Oncology Committee of ESMO.
2013-2014: President-Elect, 2014-2016 President and 2016-2018 Past-President of ESTRO.
2016 – 2017: Chair of the ECCO Oncopolicy Committee.
2017: President-Elect, 2018-2019 President and 2020 Past-President of ECCO.
ESTRO School of Radiotherapy and Oncology (currently):
– Course director of the teaching courses “Multidisciplinary Management of Breast Cancer” and “Accelerated Partial Breast Irradiation”;
– Liaison person for the multidisciplinary courses;
On top, I contributed to numerous book chapters and co-edited 2 books.
Honorary membership of BVRO/ABRO since 2012, of ESSO since 2014, of SEOR since 2015, of AROI from 2016, of BIGOSA from 2016 and of JASTRO from 2017 on. 2011 and 2012 nominated as “Toparts” (Outstanding doctor) by the Dutch radiation oncologists. In 2016, I gave the Cridlan lecture during the meeting of the Association of Breast Surgery in Manchester, UK. I received the Jens Overgaard Award from ESTRO in 2019 and the Klaas Breur Award from ESTRO in 2020. On 17 March 2021, I received the St.Gallen Breast Cancer Award.
- Christopher Pyke
Dr Chris Pyke is Associate Professor of Surgery at the University of Queensland, based at the Mater Hospital in Brisbane.
He is a former President of the Breast Surgeons Society of Australia and New Zealand (BreastSurgANZ).
His Research interests include Personalized Medicine, Oncoplastic Surgery and Quality Assurance in Breast Cancer Surgery.
- Mark Robson
Mark E. Robson, MD
Chief, Breast Medicine Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
Dr. Robson graduated from the University of Virginia School of Medicine in Charlottesville, Virginia, and did his internal medicine residency and hematology-oncology fellowship training at Walter Reed Army Medical Center in Washington DC. He is currently Chief of the Breast Medicine Service in the Department of Medicine at Memorial Hospital in New York, Attending Physician on Breast Medicine and Clinical Genetics Services, and a Member of the Memorial Sloan Kettering Cancer Center. His clinical research has concentrated on the optimal application of germline information to the management of cancer patients, particularly those with breast cancer. He has been a lead investigator for a number of trials of PARP inhibitors in patients with BRCA mutation – associated breast cancer. In addition to studying PARP inhibition as a therapeutic strategy, he is currently developing new models for the acquisition of germline information, including “mainstreaming” through test ordering by primary oncology providers and broad genomic screening in the context of somatic mutational profiling. He is also investigating the use of polygenic risk scores in facilitating decision-making among women with or without an inherited predisposition. He is an associate editor for the Journal of the National Cancer Institute. He is a Fellow of the American Society of Clinical Oncology, past Chair of the Ethics Committee of that organization and has served several terms on the ASCO Cancer Prevention Committee and its Cancer Genetics subcommittee.
- Christobel Saunders
Professor Christobel Saunders AO, is internationally recognised as one of Australia’s most prominent research-orientated cancer surgeons. She has substantially contributed to breast cancer research including clinical trials of new treatments, psychosocial, translational and health services research and is active in several areas of surgical oncology cancer research, with a particular emphasis on breast cancer. In recognition of her sustained career excellence and innovation, Christobel has been publicly acknowledged through numerous awards and honours the most recent being the AO (Order of Australia) (2018), Uccio Querci della Rovere Award (2018), International Women’s Day WA Women’s Hall of Fame Inductee (2018) and WA Scientist of the Year (2017). She has performed research for >30 years evaluating the efficacy and utility of therapy for early breast cancer. In the past five years, Christobel has published over 100 peer-reviewed journal articles (two in The Lancet), six letters to the editor/editorials, two research reports, two book chapters and one book. She sits on the boards of a number of cancer organisations including the ANZ Breast Cancer Trials Group. Christobel is closely involved in strategic planning and management of cancer services in Western Australia as author of the WA Health Cancer Services Framework and as first A/Director, WA Cancer and Palliative Care Network, past President of the Cancer Council WA, past President of the Breast Surgical Society of ANZ, and nationally as past Advisory Council member of organisations such as Cancer Australia. She is the Inaugural Chair of the state Health Service Provider, PathWest Laboratory Medicine..
- Catherine Shannon
Dr Catherine Shannon is Senior Medical Oncologist at the Mater Cancer Care Centre, Director of Medical Oncology Clinical trials unit, a member of Mater Research’s Clinical Research group and Senior Lecturer at the University of Queensland, Brisbane, Australia. She is the Principal or Co-investigator on a number of Phase I, II and III clinical trials in breast and gynaecological cancer. She is currently on the Executive Committee of the Australian Society of Breast Disease and member of the Breast cancer advisory panel for Cancer Australia.
Dr Shannon has a special interest in the management of breast cancer in young women and pregnant women and has published in this field. Dr Shannon recently started a private practice at the Mater Cancer Care Centre in South Brisbane. Her research publications include the molecular genetics of synchronous gynaecological tumours and neoadjuvant therapies for breast cancer. Dr Shannon acted as Chair at the committee for writing endocrine therapy guidelines for the management of advanced breast cancer.
- Cameron Snell
Cameron Snell, Australia
- Alastair Thompson
Professor Alastair Thompson trained and practiced as a clinician-scientist focused on multidisciplinary patient care alongside translational “bench to bedside” studies and innovative clinical trials in cancer. He initiated and led a successful breast cancer laboratory program and provided leadership for a cancer center in Dundee, United Kingdom (UK). He chaired the UK national breast cancer trials portfolio of 120 studies led the national breast cancer tissue bank and engaged in a range of pivotal roles in key drug, radiation therapy and surgical trials involving the UK, Europe, the United States and Australia. Since moving to the US in 2014, he has focused on improving treatment for breast cancer patients with innovative surgical techniques and clinical trials.
Thompson is an active member of SSO, ASBrS, ASCO and AACR. With successful peer reviewed funding from US government and international charitable sources spanning laboratory to clinical studies, successful supervision of 24 postgraduate students to date and over 400 publications in the highest impact factor clinical and scientific journals. His key mission remains improving care for those with cancer.
- Dean Trotter
Dean Trotter is the head of the Plastic & Reconstructive Surgery unit at the Women’s Hospital, Melbourne and clinical lead of the breast reconstruction service at the Royal Melbourne Hospital. He completed a fellowship in microsurgery at the St Andrew’s Centre in the UK in 2009-10 and has performed over 850 breast reconstructions in both public and private practice since his return to Melbourne in 2011. Dean has a sub-speciality interest in breast reconstruction following risk-reduction mastectomy.
- Jane Turner
Jane Turner has worked for 25 years as a consultation-liaison psychiatrist in oncology. She has extensive experience in the development and implementation of clinical practice guidelines. She was an Investigator on the successful Australian multi-site trial of a manual-based intervention for fear of cancer recurrence.
She is President-Elect of the International Psycho-Oncology Society (IPOS) and chairs the IPOS-WHO committee which aims to promote psychosocial care in low and middle-income countries. In this capacity she is engaged in initiatives to embed psychosocial care in clinical practice and national cancer control plans.
- Owen A. Ung
Professor Owen A. Ung MBBS FRACS FAICD
Owen Ung is a breast and endocrine surgeon and Director of the Metro North Comprehensive Breast Cancer Institute. He is a committed clinician, educator and researcher.
Professor of Surgery, University of Queensland
Visiting specialist – the Royal Brisbane and Women’s Hospital, Wesley Private and St Andrews War Memorial Hospital in Brisbane, Queensland, Australia.
Federal Counciller for the Australian Medical Association (AMA) and the Royal Australasian College of Surgeons (RACS) – Director Medical Insurance Australia (MIGA) – President Elect and executive member of Breast Surgery International (BSI) of the international Surgical Society (ISS).
Owen has obtained extensive administrative and management experience through his various clinical leadership roles and is active on numerous State and National Committees.
- Frank A. Vicini
Frank A. Vicini, USA
- Melanie Walker
Melanie Walker is a specialist breast surgeon in private and public practice in Melbourne.
She is the current President of BreastSurgANZ, a founding member of the Society and has held various roles on Council and the Executive Council since the Society’s inception.
After graduating from Monash University in 1996 and training in general surgery at the Alfred Hospital, she undertook a further three years of training in breast surgery in the UK, including an Oncoplastic Fellowship year at the Canniesburn Plastic Surgery Unit, Glasgow, where she developed her special interest in oncoplastic breast surgery and breast ultrasound. Melanie is committed to ensuring standards in the training and credentialing of breast surgeons.
- Sanjay Warrier
Associate Professor Sanjay Warrier is a dedicated and compassionate Consultant Breast Oncology and Oncoplastic Surgeon at Chris O’Brien Lifehouse, Royal Prince Alfred and Mater Hospitals. He is also a Visiting Medical Officer at BreastScreen NSW.
He completed his undergraduate medical training at the University of New South Wales in 2002 with post fellowship training specialising in breast oncology and oncoplastic surgery within Prince of Wales and the Royal Prince Alfred Hospital networks.
In 2013, Sanjay’s work on Hedgehog signaling, in collaboration with Garvan Institute, won the Patron’s Prize at RPAH for best scientific oral presentation.
He is an Associate Professor at the University of Sydney with the Royal Prince Alfred Institute of Academic Surgery and is the lead researcher at the Institute with the goal to improve patient outcomes through the application of the latest research and innovative technology available both in Australia and around the world.
In 2017 Sanjay was the pioneer surgeon in Australia of the SPY Elite System in his theatres. This technology is the most advanced fluorescent imaging system in the world to accurately identify healthy blood flow around remaining tissue, assisting with the decisions for immediate breast reconstructive surgery following breast-gland removal.
A/Prof Warrier is the Course Co-Founder and Co-Coordinator of the Oncoplastic Masters Course at the University of Sydney.
Sanjay is a Board member of the Sydney Breast Cancer Foundation, a role that he is honoured to hold.
He is the current Chairman of Post-Fellowship Training for BreastSurgANZ, a role that involves training of future breast surgeons in Australia and New Zealand, and the current Site Director of Surgical Training at RPAH.
Sanjay is passionate about patient care, teaching, research and in the past year has presented at various national and international conferences.
- Shane White
Shane White After completing his medical oncology training in Melbourne, Shane worked at the Christie Hospital in Manchester UK and completed a Doctorate in Medicine in 1999.
He is the former director of medical oncology at the Northern Hospital and a current staff specialist at the Austin Hospital, with interests in breast and lung cancer.
Shane is a principal investigator of breast and lung cancer research studies at the Austin and a member of the Breast Cancer Trials Group (BCTG).
- Nicholas Wilcken
Associate Professor Nicholas Wilcken MB BS, PhD, FRACP,
Nicholas Wilcken is Director of Medical Oncology at the Crown Princess Mary Cancer Centre Westmead, Senior Staff Specialist at Nepean Hospital, and Associate Professor of Medicine, University of Sydney, Australia.
Medical oncology training was at Royal Prince Alfred Hospital, Sydney, followed by a PhD in breast cancer cell cycle control at the Garvan Institute, Sydney.
His clinical interests are in breast cancer and colo-rectal cancer. Research interests include translational oncology, systematic reviews and breast cancer clinical trials.
He is currently the Co-ordinating Editor of the Cochrane Collaboration’s Breast Cancer Group and Chair of the ANZ Breast Cancer Trials Group, Scientific Advisory Committee. He has been an invited expert panel member for the last two St Gallen Early Breast Cancer Consensus Conferences in Switzerland and is a member of the Steering Committee of the Early Breast Cancer Trialists’ Collaborative Group, based in Oxford, UK.
- Belinda Yeo
Dr Belinda Yeo (FRACP, MD, MBBS, BA)
Dr Belinda Yeois jointly appointed to the Austin Hospital as a Medical Oncologist and to the Olivia Newton-John Cancer Research Institute as a Clinician Scientist with a specific interest in breast cancer. She trained in Sydney before joining the Breast Unit at The Royal Marsden Hospital, London as a Clinical and Research Fellow. She completed a Master’s Degree at The University of London and The Institute of Cancer Research in novel genomic and non-molecular breast cancer risk assays. She is a clinical trial investigator and continues her translational research at the ONJ Centre investigating improving personalization and minimising toxicities for patients with breast cancer.
- Nick Zdenkowski
Dr. Nick Zdenkowski is a medical oncologist with a predominant breast cancer focus in his multidisciplinary clinical practices at Lake Macquarie and Maitland Private Hospitals in NSW Australia. He is a conjoint senior lecturer with the University of Newcastle and works as a medical advisor to Breast Cancer Trials, Australia’s collaborative breast cancer research group, across their trials program. His research interest is in neoadjuvant systemic therapy for breast cancer, and in shared decision-making for cancer patients. His PhD thesis led to the development of a decision aid for the neoadjuvant population.
- Phillip Good